What Trump's Most-Favored-Nation Deal Means for Drug Prices
A deal with pharmaceutical companies may not be as far-reaching as the administration says, according to experts.
The Trump Administration unveiled agreements on August 31, 2026, with nine mid-sized pharmaceutical companies to reduce Medicaid drug prices, bringing the total to 26 such deals. These "most-favored-nation" prices align with those paid in countries like Europe. The administration asserts that these deals cover 90% of the drugs used in the U.S. and will be accessible via TrumpRx.gov, allowing patients to buy drugs at cash prices.
President Trump emphasized that the U.S. now pays the lowest drug prices globally. The nine new companies join the 17 that had previously agreed to most-favored-nation deals. The administration claims these agreements will cover most drugs used by Americans and will encourage pharmaceutical production in the U.S. in exchange for relief from tariffs.
While some experts suggest the main beneficiaries are states and federal governments, potentially saving billions, others warn that companies might exploit the deal by delaying market entry in certain countries or raising prices elsewhere. Critics also point out that the deal primarily benefits Medicaid users, who already pay minimal drug costs, and does little to address the underlying reasons behind the high U.S. drug prices.
Written by urgent.news from Time's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
